Organ On A Chip: Advancing New Approach Methodologies

Battelle is at the forefront of advancing new approach methodologies (NAMs) that offer alternatives to traditional animal models in toxicology testing and drug development. By leveraging in vitro and computational models, these methodologies improve accuracy, reduce costs, and accelerate research, addressing the growing demand for more efficient and human-relevant testing solutions.

One key area of focus is predictive inhalation biology. Inhalation exposure is critical for assessing the effects of airborne chemicals, pathogens, and drug administration. However, traditional animal models often fail to accurately replicate human respiratory biology, leading to challenges in predicting health impacts. To address this, Battelle employs advanced in vitro models, such as 3D respiratory cell cultures and lung-on-a-chip technology, to provide more precise, scalable, and ethical testing solutions.

The air-liquid interface exposure system enables controlled, real-time assessments of inhaled substances. Using high-throughput platforms like the VITROCELL 24/48 system, Battelle can evaluate complex mixtures, chemicals, and pathogens over extended exposure periods. Continuous monitoring ensures accurate dose measurements and reliable predictions of human health effects.

By integrating data across molecular, organelle, cellular, tissue, and organ levels, Battelle builds predictive models that streamline regulatory approval and enhance drug safety assessments. These innovations not only refine toxicology and inhalation studies but also support a broader shift toward data-driven, human-relevant testing methodologies.

Battelle’s commitment to pioneering NAMs is transforming the landscape of biomedical research, making drug development and safety evaluations faster, more cost-effective, and scientifically rigorous.